• Je něco špatně v tomto záznamu ?

Understanding PACS2 syndrome's pathomechanism by studying E209K and E211K mutations

A. Zbikowski, T. Kowalczyk, P. Kasparek, J. Prohazka, R. Sedlacek, M. Ciborowski, D. Cysewski, K. Łukasiewicz

. 2025 ; 36 (2) : 363-371. [pub] 20241230

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015577

Grantová podpora
B.SUB.24.525 Uniwersytet Medyczny w Bialymstoku
Visegrad Fellowship #62410114 International Visegrad Fund

Phosphofurin acidic cluster sorting protein 2 (PACS2) plays a vital role in maintaining cellular homeostasis by regulating protein trafficking between cellular membranes. This function impacts crucial processes like apoptosis, mitochondria-endoplasmic reticulum interaction, and subsequently Ca2+ flux, lipid biosynthesis, and autophagy. Missense mutations, particularly E209K and E211K, are linked to developmental and epileptic encephalopathy-66 (DEE66), known as PACS2 syndrome. Individuals with this syndrome exhibit neurodevelopmental delay, seizures, facial dysmorphism, hypotonia, and delayed motor skills.Understanding the impact of these missense mutations on molecular processes is crucial. Studies suggest that E209K mutation decreases phosphorylation, increases the survival time of protein, and modifies protein-protein interaction, consequently leading to disruption of calcium flux and lower resistance to apoptosis induction. Unfortunately, to date, only a limited number of research groups have investigated the effects of mutations in the PACS2 gene. Current research on PACS2 syndrome is hampered by the lack of suitable models. While in vitro models using transfected cell lines offer insights, they cannot fully capture the disease's complexity.To address this, utilizing cells from individuals with PACS2 syndrome, specifically induced pluripotent stem cells (iPSCs), holds promise for understanding phenotypic diversity and developing personalized therapies. However, iPSC models may not fully capture tissue-specific effects of the E209K/E211K mutation. In vivo studies using animal models, particularly mice, could overcome these limitations.This review summarizes current knowledge about PACS2 structure and functions, explores the cellular consequences of E209K and E211K mutations, and highlights the potential of iPSC and mouse models in advancing our understanding of PACS2 syndrome.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015577
003      
CZ-PrNML
005      
20250731091106.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00335-024-10098-5 $2 doi
035    __
$a (PubMed)39738582
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zbikowski, Arkadiusz $u Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland
245    10
$a Understanding PACS2 syndrome's pathomechanism by studying E209K and E211K mutations / $c A. Zbikowski, T. Kowalczyk, P. Kasparek, J. Prohazka, R. Sedlacek, M. Ciborowski, D. Cysewski, K. Łukasiewicz
520    9_
$a Phosphofurin acidic cluster sorting protein 2 (PACS2) plays a vital role in maintaining cellular homeostasis by regulating protein trafficking between cellular membranes. This function impacts crucial processes like apoptosis, mitochondria-endoplasmic reticulum interaction, and subsequently Ca2+ flux, lipid biosynthesis, and autophagy. Missense mutations, particularly E209K and E211K, are linked to developmental and epileptic encephalopathy-66 (DEE66), known as PACS2 syndrome. Individuals with this syndrome exhibit neurodevelopmental delay, seizures, facial dysmorphism, hypotonia, and delayed motor skills.Understanding the impact of these missense mutations on molecular processes is crucial. Studies suggest that E209K mutation decreases phosphorylation, increases the survival time of protein, and modifies protein-protein interaction, consequently leading to disruption of calcium flux and lower resistance to apoptosis induction. Unfortunately, to date, only a limited number of research groups have investigated the effects of mutations in the PACS2 gene. Current research on PACS2 syndrome is hampered by the lack of suitable models. While in vitro models using transfected cell lines offer insights, they cannot fully capture the disease's complexity.To address this, utilizing cells from individuals with PACS2 syndrome, specifically induced pluripotent stem cells (iPSCs), holds promise for understanding phenotypic diversity and developing personalized therapies. However, iPSC models may not fully capture tissue-specific effects of the E209K/E211K mutation. In vivo studies using animal models, particularly mice, could overcome these limitations.This review summarizes current knowledge about PACS2 structure and functions, explores the cellular consequences of E209K and E211K mutations, and highlights the potential of iPSC and mouse models in advancing our understanding of PACS2 syndrome.
650    _2
$a lidé $7 D006801
650    12
$a vezikulární transportní proteiny $x genetika $x metabolismus $7 D033921
650    _2
$a zvířata $7 D000818
650    12
$a missense mutace $7 D020125
650    _2
$a indukované pluripotentní kmenové buňky $x metabolismus $7 D057026
650    _2
$a mutace $7 D009154
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kowalczyk, Tomasz $u Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland
700    1_
$a Kasparek, Petr $u Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic
700    1_
$a Prohazka, Jan $u Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic
700    1_
$a Sedlacek, Radislav $u Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic
700    1_
$a Ciborowski, Michał $u Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland
700    1_
$a Cysewski, Dominik $u Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland. dominik.cysewski@umb.edu.pl
700    1_
$a Łukasiewicz, Kacper $u Experimental Medicine Centre, Medical University of Bialystok, Bialystok, Poland. kacper.lukasiewicz@umb.edu.pl $u Department of Psychiatry, Medical University of Bialystok, Bialystok, Poland. kacper.lukasiewicz@umb.edu.pl
773    0_
$w MED00003189 $t Mammalian genome $x 1432-1777 $g Roč. 36, č. 2 (2025), s. 363-371
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39738582 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091101 $b ABA008
999    __
$a ok $b bmc $g 2366433 $s 1252702
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 36 $c 2 $d 363-371 $e 20241230 $i 1432-1777 $m Mammalian genome $n Mamm Genome $x MED00003189
GRA    __
$a B.SUB.24.525 $p Uniwersytet Medyczny w Bialymstoku
GRA    __
$a Visegrad Fellowship #62410114 $p International Visegrad Fund
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...